Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BU 2722/2-3, HA 6880/2-3)
Government of Canada's New Frontiers in Research Fund (NFRFT-2020-00787)
European Union’s Horizon 2020 Research and Innovation Program (825392; RESHAPE consortium)
Medizinische Hochschule Hannover (MHH)
Received: 4 October 2022
Accepted: 4 December 2022
First Online: 10 December 2022
: The animal study protocol was approved by the animal welfare commission of the Hannover Medical School and local ethics animal review board (Lower Saxony State Office for Consumer Protection and Food Safety, Oldenburg, Germany) by the applications 06/1137, 11/0342, and 16/2116.
: Not applicable.
: M.P.M. declares being an ad hoc consultant at Roche for AIH therapies. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The other authors declare no conflict of interest.